Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study

OBJECTIVE: PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one...

Descripción completa

Detalles Bibliográficos
Autores principales: Östör, Andrew, Van den Bosch, Filip, Papp, Kim, Asnal, Cecilia, Blanco, Ricardo, Aelion, Jacob, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Padilla, Byron, Kivitz, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234194/
https://www.ncbi.nlm.nih.gov/pubmed/36282537
http://dx.doi.org/10.1093/rheumatology/keac605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234194/
https://www.ncbi.nlm.nih.gov/pubmed/36282537
http://dx.doi.org/10.1093/rheumatology/keac605

Ejemplares similares